61727-34-2

Usage

Uses

Used in Pharmaceutical Industry:
5-PYRIMIDINEACETIC ACID, 4-CHLORO-2-(METHYLTHIO)-, ETHYL ESTER is used as a key intermediate compound for the synthesis of dihydropyrrolopyrimidine-selective JAK2 inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various diseases, including cancer and autoimmune disorders. 5-PYRIMIDINEACETIC ACID, 4-CHLORO-2-(METHYLTHIO)-, ETHYL ESTER's unique structure allows it to interact with specific protein targets, modulating their activity and potentially leading to therapeutic benefits.
In the preparation of JAK2 inhibitors, 5-PYRIMIDINEACETIC ACID, 4-CHLORO-2-(METHYLTHIO)-, ETHYL ESTER serves as a building block that can be further modified and optimized to enhance the potency, selectivity, and pharmacokinetic properties of the final drug candidates. This makes it a valuable asset in the ongoing efforts to develop novel and effective treatments for a wide range of medical conditions.

InChI:InChI=1/C9H11ClN2O2S/c1-3-14-7(13)4-6-5-11-9(15-2)12-8(6)10/h5H,3-4H2,1-2H3

Upstream product

• 14273-44-0 Hydroxymethylen-bernsteinsaeure-diethylester 
• 123-25-1 succinic acid diethyl ester 
• 5472-38-8 diethyl 2-formylbutanedioate 
• 29571-44-6 ethyl 2-[4-hydroxy-2-(methylthio)pyrimidin-5-yl]acetate 

Relevant academic research and scientific papers

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Convenient synthesis of 2-substituted 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones

A new synthetic route was elaborated at our laboratory providing a convenient access to 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones (diazaoxindoles), a compound family of biological relevance. Treatment of the easily available ethyl 2-(4-chloropyrimidin-5-yl)acetate derivatives with ammonia afforded the corresponding 2-(4-aminopyrimidin-5-yl)acetamides, which were finally cyclized to the target compounds.

5,7-DIHYDRO-6H-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVES FOR MARK INHIBITION

Compounds of formula I: are potent and selective inhibitors of microtubule affinity regulating kinase (MARK), and hence find use in treatment of Alzheimer's disease and other conditions associated with hyperphosphorylation of tau.